MedTrace Logo

A Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity

NCT00983645 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-06-03

Study results available
· View outcomes & findings →

Summary

This study aims to compare outcomes in renal transplant recipients in the hispanic population based on their immunosuppressant regimens.

Conditions

  • Renal Transplant Rejection

Interventions

DRUG

Prograf

Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID

DRUG

Neoral

Cyclosporine (Neoral) starting dose 3mg/kg PO BID

Sponsors & Collaborators

  • Loma Linda University

    lead OTHER

Principal Investigators

  • Pedro Baron, MD · Loma Linda University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2012-10-31
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00983645 on ClinicalTrials.gov